1. Scrip

BMS/Janssen Will Begin Phase III For Factor XIa Inhibitor Milvexian By Year-End

Phase II Showed Potential Beyond Prior Anticoagulants

 
• By Mandy Jackson

Bristol and Janssen reported Phase II data at the ESC Congress in secondary stroke prevention, an indication not covered by Factor Xa inhibitors. BMS unveiled a three-indication Phase III program.

stethoscope twisted in heart shape lying on cardiogram chart closeup
BMS unveiled three Phase III indications: secondary stroke prevention, acute coronary syndrome and atrial fibrillation • Source: Shutterstock

With data in hand from two Phase II clinical trials of milvexian, Bristol Myers Squibb Company and the Janssen Pharmaceutical Cos. of Johnson & Johnson now plan to kick off a Phase III program later this year to show definitively whether the Factor XIa inhibitor can be developed beyond the approved indications for the class’s predecessors – Factor Xa inhibitors, such as the BMS/Pfizer Inc. blockbuster anticoagulant Eliquis (apixaban).

Bristol and Janssen presented positive Phase II results on 28 August at the European Society of Cardiology (ESC) Congress in Barcelona from the AXIOMATIC-SSP trial testing milvexian in secondary stroke prevention (SSP)

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Cardiovascular

More from Therapy Areas

Shionogi In $1bn Deal For Japan Tobacco’s Pharma Ops

 
• By Ian Haydock

Mid-sized Japanese pharma firm to acquire tobacco giant’s pharma operations and take private the listed Torii Pharmaceutical business, in bid to build sales reach and strengthen manufacturing.

Copycats Compound Novo’s Wegovy Growth Problems

 
• By Andrew McConaghie

The US FDA has ordered compounders of the Danish firm's obesity drug semaglutide to shut up shop later this month, but competition from Eli Lilly is only increasing.

First Win For AstraZeneca’s Enhertu In Early-Stage Breast Cancer Treatment

 
• By Andrew McConaghie

Already dominating in later lines of breast cancer treatment, Enhertu could now displace both chemotherapy combinations and Roche’s Kadcyla in early-stage HER2-positive patients.